ENHERTU (Trastuzumab Deruxtecan) — Next-Generation ADC for HER2+ Breast Cancer
July 03, 2026
ENHERTU is a next-generation antibody-drug conjugate (ADC) combining Trastuzumab and a chemotherapy payload, selectively eliminating HER2-positive breast cancer cells. For reference.
What is ENHERTU?
ENHERTU (Trastuzumab deruxtecan, T-DXd) is a next-generation antibody-drug conjugate (ADC): the Trastuzumab antibody guides the drug to HER2+ cells, then releases the chemotherapy payload deruxtecan to destroy cancer cells from within. Compared to Trastuzumab alone, ENHERTU has greater potency and also acts on HER2-low cells.
Clinical Advantages
Effective in heavily pre-treated HER2+ breast cancer and HER2-low breast cancer — a patient group that previously could not benefit from HER2-targeted therapy. ENHERTU is also being studied in HER2+ lung and gastric cancers.
In China
ENHERTU and next-generation ADCs are accessible at major oncology centres in China, particularly through the Hainan Medical Free Trade Zone where drugs not yet approved for the mainland can still be used.
Disclaimer
Information is for reference only. The treating physician determines the protocol based on HER2 test results and the patient's specific condition.
Related Images
